Clinical trial
Meta-Iodobenzylguanidine (123I-mIBG) Scintigraphy Imaging in Patients With Heart…
NCT00126438 · GE Healthcare, Industry · Completed
Key facts
| NCT number | NCT00126438 |
|---|---|
| Title | Meta-Iodobenzylguanidine (123I-mIBG) Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease |
| Official title | An Open-Label, Multicenter, Phase 3 Study Evaluating the Prognostic Usefulness of I-123 mIBG Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience an Adverse Cardiac Event |
| Lead sponsor | GE Healthcare, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Heart Failure, Congestive |
| Intervention type | Drug |
| Interventions | 123I-mIBG (meta-iodobenzylguanidine) |
| Enrollment | 515 |
| Start date | Jul 1, 2005 |
| Primary completion | Jul 1, 2008 |
| Completion | Sep 1, 2008 |
| First posted | Aug 4, 2005 |
| Last update posted | Mar 14, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: